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Background: Human kallikrein gene 6 (KLK6) is a member of the human kallikrein gene family (Kallikreins, KLKs).
Human kallikrein-related peptidase 6 (hK6) is a trypsin-like serine protease encoded by the KLK6, has been reported
to be highly expressed in several cancers including gastric cancer. In this study, we investigated the the correlation
of hK6 expression with clinicopathological characteristics, tumor recurrence and prognosis in advanced gastric
carcinoma after curative resection.
Methods: We retrospectively analyzed the clinical data of 129 cases advanced gastric cancer after curative
gastrectomy. The expression of hK6 in advanced gastric cancer tissues compared to adjacent noncancerous tissues
were examined, and the relationship between hK6 expression and clinicopathological characteristics was evaluated.
In additional, these patients were followed up to investigate the relationship between hK6 expression and the
survival time.
Results: The positive rate of hK6 expression was significantly higher in advanced gastric cancer tissue, than that in
adjacent noncancerous and gastric ulcer tissues (36.5%, 33.3%, respectively, P < 0.001). There was a close
relationship between hK6 expression and TNM stage (P = 0.005), vascular invasion (P = 0.037) and perineural
invasion (P = 0.035). Furthermore, patients with hK6 positive showed significantly higher recurrence and poorer
prognosis than those with hK6 negative. Multivariate analysis showed that hK6 expression was a significant
independent factor for tumor recurrence and overall survival.
Conclusion: hK6 is overexpressed in advanced gastric cancer tissues. Its clinical utility may be used as an
unfavorable indicator in predicting tumor recurrence and prognosis for advanced gastric cancer after operation.
This study also suggests that hK6 might be a potential therapeutic target for gastric cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/8558403578787206
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Gastric cancer is one the most common malignancies
and the second leading cause of death among all cancers
in the clinical [1], and surgical resection remains cur-
rently the only treatment with curative. Even if the sur-
gery, postoperative chemo-radiotherapy immunotherapy,
targeted therapy those multidisciplinary collaborative* Correspondence: neuroman@163.com
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reproduction in any medium, provided the ormode have improved the survival rate of gastric cancer
patients. Still the postoperative recurrence rate of gastric
cancer is high, especially advanced gastric cancer
(Advanced gastric cancer refers to that tumor invades to
the muscularis propria or through the muscularis to ser-
osa and extra serosa). And early diagnosis is difficult, the
specific tumor markers in detection of tumor recurrence
has not yet been discovered.
The KLKs consist of 15 homologous genes which en-
coding secreted serine proteases, localized in tandem on
chromosome 19q13.4. The KLKs have similar genomicThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the nucleotide and protein level. The same gene of the
family is expressed in different tissues, and multiple
genes are commonly expressed in the same tissue [2].
KLK6 is a member of the KLKs, which encodes for hu-
man kallikrein-related peptidase 6 (hK6). It is a serine
protease made up of 223 amino acids with trypsin-like
activity. hK6 has been cloned independently by three
groups, using a differential display technique from pri-
mary and metastatic breast cancer cell lines. Anisowicz
et al. [3] first isolated the full-length cDNA of KLK6,
named protease M, which is strongly expressed at the
mRNA level in certain primary breast cancer cell lines
and in ovarian cancer tissues and cell lines. Yamashiro
et al. [4] cloned this same gene, named neurosin, from a
cDNA library prepared from a human colorectal cancer
cell line (COLO 201). Finally, Little et al. [5] cloned the
identical cDNA, named zyme, from the brain tissue of a
patient with Alzheimer’s disease, which played an im-
portant role in the development and progression of
Alzheimer’s disease. Study found that hK6 was highly
expressed in gastric cancer and indicated poor prog-
nosis [6].
To our best knowledge, few studies have been investi-
gated concerning the clinical significance of hK6 expres-
sion in advanced gastric cancer with recurrence and
prognosis. In this study, we evaluated the expression of
hK6 in the surgical specimens of advanced gastric cancer
tissues, paired adjacent noncancerous tissues and gastric
ulcer tissues using immunohistochemistry HRP, and ana-
lyzed their correlations with clinicopathological charac-
teristics and patients survival to clarify the significance
of hK6 in advanced gastric cancer after curative surgery.
Materials and methods
Patients and collection of tissue samples
A total of 129 samples were obtained from patients from
January 2007 to November 2011 who underwent cura-
tive surgery for advanced gastric cancer in HuiZhou Mu-
nicipal Central Hospital of GuangDong. Resection
samples were confirmed to be primary advanced gastric
cancer by clinical pathology, none of the patients re-
ceived any chemotherapy, radiotherapy and other adju-
vant therapy prior to operation. 52 blocks from adjacent
noncancerous gastric tissues (at least 5 cm away from
the cancer margin) were obtained from the patients. In
addition, 36 specimens obtained from patients who
underwent surgery and were confirmed to be gastric
ulcer used as controls in the same period.
Patients, clinicopathological characteristics such as
gender and age, tumor location, size, differentiation,
T stage, lymph node metastasis, TNM stage and whether
recurrence were retrospectively reviewed. The mean age
was 60 years (range: 28 ~ 80 years)with 56 women and73 men. All the patients were staged based on the TNM
classification of the American Joint Committee on Can-
cer (AJCC, 7th Edition criteria, 2010) [7].Tumor location
in gastric fundus/cardia was 21 cases, gastric body 32
cases, gastric antrum 76 cases. Tumor size was greater
than 5 cm in 70 cases, and less than 5 cm in 59 cases,
16 cases classified as well or moderately differentiated
(including tubular and papillary adenocarcinoma), 113
cases as poorly differentiated (poorly differentiated
adenocarcinoma and other cell types such as mucinous
adenocarcinoma and signet ring cell carcinoma and
so on), 19 cases were at T2, 55 cases were at T3 and T4
respectively. N0/N1 was found in 49 cases, N2/N3 in 80
cases, 43 cases withI/II stage, 86 cases with III/IV stage,
written informed consent was obtained from all patients
or their families. The study was approved by the Insti-
tute,s Ethics Committee of HuiZhou Municipal Central
Hospital. All the specimens were fixed in 10% neutral-
ized maldehyde, embedded in paraffin, cut into 3-μm
thick sections, and mounted on glass slides for immuno-
histochemistry analysis.
Immunohistochemistry
Immunohistochemistry was performed using the Horse-
radish Peroxidase two-step method, which avoids the
interference of endogenous biotin, thus reducing the
nonspecific false-positive background staining. Immuno-
histochemistry was carried out in eight steps according
to the instructions: 1, The paraffin sections were
deparaffinized in xylene, rehydrated through gradient
ethanol. 2, Antigen retrieval was performed in Tris-EDTA
buffer (pH 9.0) with a pressure cooker. 3, Block the en-
dogenous peroxidase with 3% hydrogen peroxide. 4, Then
incubated with the purified rabbit polyclonal antibody
(AP6325a, Abgent, San Diego, USA), antigen retrieval and
dilution were determined by preliminary experiments. 5,
Detection of hK6 immunocomplex was incubated with
the PV9000 kits (Golden bridge Biotechnology Co, Ltd,
Beijing, China). 6, Stained with diaminobenzidine sub-
strate chromogen solution (Goldenbridge Biotechnology
Co, Ltd) until the optimal staining was achieved. 7, The
sections were counterstained with hematoxylin, differenti-
ated, returned blue. 8, Finally, dehydrated through gradi-
ent alcohol, cleared in xylene, neutral gum mounted.
Then observed under the optical microscope.
Immunohistochemical staining score
All slides were assessed separately by two senior pathol-
ogists with no prior knowledge of clinicopathological pa-
rameters, the final score for their average. For evaluation
of hK6 immunohistochemical staining, the percentage of
positive cells was evaluated quantitatively 10 fields
within the tumor were selected randomly, expression in
1000 cancer cells (100 cells per field) was evaluated
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was evaluated quantitatively and scored as: 0 for the per-
centage of positive cells ≤ 10%, 1 for staining of 11 ~
25%, 2 for staining of 26 ~ 50%, and 3 for staining of 51
~ 75%, 4 for staining of > 75% of the cells examined [6],
the staining intensity was respectively graded semiquan-
titatively as follows: 0 no signal, 1 weak, 2 moderate, and
3 strong according to the previous literatures [8], a total
staining score of 4 or more was graded as immunohisto-
chemical positive.Follow-up
All these patients received fluorouracil based adjuvant
chemotherapy after surgery. As a regular follow-up, all
the patients were checked every 3 months during the
first 2 years and every 6 months during the third to
the fifth year, once a year thereafter. Medical work-
up consisted of history and physical examination,
hematology and biochemical tests including serum CEA,
CA19-9 and CA72-4, and imaging including chest radi-
ography, barium meal, abdominal ultrasonography (US),
computed tomography (CT), and endoscopy according
to the clinical situation. The follow-up time had the day
of surgery as a starting point, the time of tumor recur-
rence and death were recorded, these two points were
evaluated for prognostic analysis. If the follow-ups were
incomplete, patients or their families were contacted by
telephone, the closing date for follow-up was May 2012,
the median follow-up period after surgery was 25 months
(range 4–64 months).Statistical analysis
Statistical analysis was carried out using the SPSS 13.0,
the relationships between hK6 expression and patient
clinicopathological characteristics were analyzed with
the Chi-square (χ2) and Fisher’s exact test. For survival
analysis, two end points were examined:recurrence-free
survival (RFS) and overall survival (OS) respectively. RFS
is defined as the time interval between the date of sur-
gery and the date of first detected recurrence or metas-
tasis, and OS is defined as the time interval between the
date of surgery and the date of death or the date of last
follow-up for those who were alive at the end of the
study. The Kaplan–Meier model was used to examine
survival between the patients positive and negative hK6
expression. The significance of any difference in the sur-
vival curves was determined with the log-rank test. Vari-
ables achieving a significance level in the univariate
analysis were subsequently introduced in a forward LR
proportional hazard analysis (Cox’s model)to identify
those variables independently associated with survival,
the p value of 0.05 (or less)was considered as statistically
significant.Results
hK6 expression in advanced gastric cancer tissues
Different proteins were expressed in different location of
the cell, such as cytoplasm, membrane, nuclear [9,10].
hK6 positive staining was mainly expressed in the cyto-
plasm of gastric cancer cells as brown or dark brown
granules (Figure 1) also was observed in the adjacent
noncancerous and gastric ulcer epithelial cells by immu-
nohistochemistry. The positive rate of KLK6 expression
in gastric cancer tissues was 77.5% (100/129), signifi-
cantly higher than that in adjacent noncancerous tissues
(36.5%) and ulcer (33.3%) tissues respectively (P <0.001;
Table 1).
hK6 expression and clinicopathological characteristics
The correlation between hK6 expression levels and clini-
copathological characteristics is as summarized in
Table 2, hK6 expression significantly correlated with
TNM stage (P = 0.005), vascular invasion (P = 0.037) and
perineural invasion (P = 0.035). hK6 positive tumors
more frequently had later stage, an increased incidence
of vascular and perineural invasion, on the other hand,
no statistical significant difference was observed between
its expression and gender, age, tumor site, size, differen-
tiation, T stage, lymph lodes metastasis or margin
(P > 0.05).
hK6 expression association with tumor recurrence and
poor overall survival
As the follow-up ended, 68 (52.7%) patients had died, A
total of 61 patients died because of tumor progression
and 7 due to other causes. In all, there were 69 (53.5%)
patients developed tumor recurrence, 31 of whom devel-
oped as loco-regional relapse, 19 as distant metastases
(11 in liver, 3 in lung, and 5 in bone), 14 as peritoneal
recurrence and 5 as remnant; All but eight patients with
tumor recurrence died from it.
Kaplan–Meier survival curves indicated patients with
positive hK6 expression were more likely to have both a
shorter RFS (P = 0.002, Figure 2A) compared to patients
with negative hK6 expression. Univariate analysis
expression with regard to RFS, using the Cox propor-
tional hazard regression model, showed that hK6 expres-
sion, TNM stage, tumor size, T stage, lymph lodes,
margin and were influencing factors for RFS, When hK6
expression along with other factors were examined in a
multivariate model, TNM stage, hK6 expression, tumor
size, margin were independent predictors of tumor
recurrence (Table 3), indicating hK6 positive patients are
twice more likely to have a recurrence than hK6 negative
ones.
According to the survival analysis, Kaplan–Meier sur-
vival analysis showed that patients with positive hK6 ex-
pression have lower OS (P = 0.002, Figure 2B), univariate
A B
C D
Figure 1 Immunohistochemical staining of hK6 in the advanced gastric carcinoma (A, B) and adjacent noncancerous (C, D) tissues.
A hK6 positive expression; B hK6 negative expression; C hK6 positive expression; D hK6 negative expression.
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stage, tumor size, lymph node, T stage, and margin are
important factors influencing the OS rates, when these
factors were involved in a multivariate analysis (Table 4),
TNM stage and hK6 were independent prognostic fac-
tors of OS.
Multivariate analysis indicated that hK6 expression
was one of the independent prognostic factors of overall
survival for the patients with gastric cancer next to
TNM stage (P = 0.011).
Discussion
Studies found that hK6 was secreted to the extracellular
matrix and involved in the degradation of matrix pro-
teins including fibronectin, laminin, vitronectin, collagen
and induced E-cadherin ectodomain shedding, reduced
the cell-cell adhesion [11,12] and led to keratinocyte to
promote tumor proliferation, migration, invasion and
metastasis [13]. It is known that human hK6 is areTable 1 The expression of hK6 in adjacent noncancerous,
gastric ulcer and advanced gastric cancer tissues
Group Cases Positive Positive rate χ2-value P-value
GCT 129 100 77.5% 39.201 <0.001a
ANT 52 19 36.5% 0.096 0.757b
GUT 36 12 33.3%
Abbreviation: ANT, Adjacent noncancerous tissues; GUT, Gastric ulcer tissues;
GCT gastric cancer when GCT compared to ANT and GUT, P < 0.001, ANT
compared to GUT, P = 0.757.involved in several malignancies, Several scholars have
reported that hK6 is overexpressed in ovarian cancer
[14], uterine serous papillary cancer [15], colorectal can-
cer [16], gastric cancer [6] and esophageal cancer [17],
but underexpressed in salivary gland tumors [18] and
renal cell carcinoma [19], which depends on the tumor
tissue types and microenvironment [20]. hK6 promotes
the growth of most tumors. However, when hK6 was
overexpressed in breast cancer MDA-MB-231 cells, cells
were resulted in marked reversal of their malignant
phenotype, manifested by lower proliferation rates and
saturation density, marked inhibition of anchorage inde-
pendent growth, reduced cell motility and ability to form
tumors. The mechanism may be that hK6 play a protect-
ive role against tumor progression mediated by inhib-
ition of epithelial-to-mesenchymal transition [21].
To date, it has been shown that KLK6 is upregulated
in such gastrointestinal malignancies as pancreatic and
colon cancers [22]. Ogawa et al. [16] reported that KLK6
mRNA expression was significantly higher in cancerous
than in corresponding noncancerous colorectal tissue.
Kim et al. [23] examined the KLK6 mRNA and its corre-
sponding protein levels using RT-PCR and ELISA, found
that KLK6 mRNA was upregulated by about 8-fold,
compared to nontumor regions, and serum hK6 levels
from gastric cancer patients was 1.7-fold to healthy indi-
viduals. When inactivating KLK6 with small interference
RNA(siRNA), cellular invasiveness decreased by 45%. He
also discovered that KLK6 degrade extracellular matrix
Table 2 The relationship between KLK6 expression, tumor recurrence and clinicopathological characteristics
Characteristics Cases Positive Positive rate χ2-value P-value
Gender 1.214 0.271
Female 56 46 82.1%
Male 73 54 74.0%
Age 0.067 0.796
<60 years 65 51 78.5%
≥60 years 64 49 76.6%
Tumor site 3.806 0.149
fundus/cardia 21 19 90.5%
body 32 26 81.3%
antrum pylorus 76 55 72.4%
Tumor size 0.540 0.462
<5 cm 59 44 74.6%
≥5 cm 70 56 80.0%
Differentiation 0.004 0.951
Well/moderate differentiated 16 16 13 81.3%
Poorly differentiated 113 87 77.0%
T stage 1.486 0.476
T2 19 13 68.4%
T3 55 45 81.8%
T4 55 42 76.4%
Lymph node 1.682 0.195
N0/N1 49 35 71.4%
N2/N3 80 65 81.3%
Vascular invasion 4.370 0.037
Absent 81 58 71.6%
Present 48 42 87.5%
Perineural invasion 4.439 0.035
Absent 76 54 71.1%
Present 53 46 86.8%
Margin 0.211 0.646
Absent 110 84 76.4%
Present 19 16 84.2%
TNM stage 8.029 0.005
I + II 43 27 62.8%
III + IV 86 73 84.9%
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ous overexpression of KLK6 led to decreased activity of
the E-cadherin promoter. Moreover, our study showed
the positive rate of hK6 expression in advanced gastric
cancer tissue was significantly higher than that in adja-
cent noncancerous and gastric ulcer tissue. However, no
difference was found between adjacent noncancerous
tissue and gastric ulcer tissue. These findings suggest
that hK6 expression may play an important role in gas-
tric cancer development.Ogawa et al. [16] reported that high KLK6 mRNA ex-
pression levels in colorectal cancer tissues were corre-
lated with serosal invasion, liver metastasis, advanced
Duke’s stage, However, limited reports suggested the re-
lationship between KLK6 expression and clinicopatho-
logical characteristics. Nagahara et al. [6] reported that
the overexpression of KLK6 was significantly associated
with TNM stage, lymphatic invasion for patients with
gastric cancer. In the current study, for the TNM stage,
the positive rate of hK6 expression was significantly
Figure 2 Kaplan–Meier survival curves shows the probability of being free of recurrence (A) and overall survival (B) in patients with
hK6-negative and hK6-positive expression. Abbreviations: 95% CI 95% confidence interval, HR hazard ratio, OS overall survival, RFS
recurrence-free survival.
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that in earlier stage (stage I and stag II: 62.8%). The dif-
ference was statistically significant, demonstrating that
hK6 positive expression was strongly correlated with
TNM stage in advanced gastric cancer. Our study also
showed that there was a relationship between hK6Table 3 Univariate and multivariate analysis of hK6 and othe
advanced gastric cancer
Univariate
Variable HR 95% CI
Gender F/ M 1.05 0.65 -1 .69
Age < 60/ ≥60 yr 1.30 0.81- 2.08
Tumor site – –
body/fundus 0.68 0.31-1.49
antrum/fundus, body 0.88 0.45 -1.71
Tumor size < 5/ ≥5 cm 2.05 1.25 - 3.37
grade Well/Poorly 0.88 0.40 -1.93
T stage – –
T3/T2 2.21 0.92-5.30
T4/T2,T3 2.60 1.08 -6.26




TNM stage I,II/III,IV 3.10 1.69-5.68
hK6−/+ 2.77 1.41-5.47positive expression with vascular invasion, which was
consistent with Nagahara’s [6] report. Additionally, It
was reported that hK6 positive expression was associated
with perineural invasion, which not studied in
Nagahara’s [6] report, but it needs further study to verify.
We found no relationship between hk6 expression inr clinicopathological characteristics with regard to RFS in
Multivariate
P HR 95% CI P
0.86 – – –
0.29 – – –
0.58 – – –
0.33 – – –
0.70 – – –
0.005 1.80 1.07 – 3.04 0.027
0.75 – – –
0.10 – – –
0.077 – – 0.58
0.032 – – 0.75
0.002 – – 0.83
0.77 – – –
0.42 – – –
0.001 2.49 1.44– 4.31 0.001
0.000 2.25 1.18 –4.30 0.014
0.003 2.09 1.04 –4. 230.039
Table 4 Univariate and multivariate analysis of prognostic factors of OS in advanced gastric cancer
Univariate Multivariate
Variable HR 95% CI P HR 95% CI P
Gender F/M 1.35 0.80-2.25 0.26 – – –
Age < 60/≥60 yr 1.59 0.95-2.67 0.08 – – –
Tumor site – – 0.17 – – –
body/fundus 0.47 0.20-1.09 0.078 – – –
antrum/fundus, body 0.57 0.29 -1.13 0.11 – – –
Tumor size < 5/ ≥5 cm 1.72 1.02-2.90 0.043 – – 0.57
grade Well/Poorly 0.57 0.26-1.27 0.17 – – –
T stage – – 0.004 – – 0.019
T3/T2 1.60 0.66-3.89 0.30 0.83 0.33–2.12 0.70
T4/T2,T3 3.36 1.38–8.15 0.007 1.86 0.73–4.70 0.19
N stage N0,N1/N2,N3 2.87 1.57–5.21 0.001 – – 0.12
Vascular−/+ 1.23 0.65-2.34 0.52 – – –
Perineural−/+ 1.32 0.71-2.43 0.38 – – –
Margin−/+ 1.29 0.72-2.31 0.40 – – –
TNM stage I,II/III,IV 4.05 2.04– 8.03 <0.001 2.99 1.45–6.16 0.003
hK6−/+ 2.88 1.40-5.92 0.004 2.66 1.25–5.63 0.011
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tumor site, size, differentiation, T stage, lymph lode
metastasis, which was in agreement with previous
results [6].
A plenty of evidence has demonstrated that several
members of the KLKs are potential cancer biomarkers
[24]. The most widely known and used KLKs is KLK3.
KLK3 gene encodes prostate-specific antigen (hK3), has
been approved by the US FDA as the specific marker of
prostate cancer, which is widely used for screening, diag-
nosing, determining the efficacy and assessing the prog-
nosis of prostate cancer [25]. KLK2 protein (hK2), is also
considered as a secondary marker of prostate cancer. Re-
cent reports have indicated that hK6 high expression in
ovarian cancer [26], colon cancer [16,27], pancreatic
cancer [28], non-small cell lung cancer [29] and intracra-
nial tumors [30] could be an independent prognostic
factor, suggesting that hK6 may be a prognostic marker
for these tumors.
Studies have suggested that high KLK6 expression was
closely associated with shorter overall and recurrence-
free survival for ovarian cancer [31] and colon cancer
patients [32]. The same result was confirmed in ad-
vanced gastric cancer in our study. All of these suggest
that KLK6 may be a potential biomarker in predicting
tumor recurrence and therapeutic target for them. Many
studies consistently showed that TNM stage was the
most reliable prognostic indicator of gastrointestinal neo-
plasms such as gastric carcinoma, gastrointestinal lymph-
omas patients [9,10,33,34], while other characteristics,there was no agreement. Jin et al. [33] found Ezrin
overexpression increased significantly in lymph node me-
tastasis, Demirag et al. [10] showed PKP3 expression and
poor prognosis appeared to correlate with lymph node
number. While in the present study, we did not find any as-
sociation between lymph node metastasis and prognosis in
multivariate analysis.
With the development of molecular and proteomics in
gastric cancer, many proteins have been the potential
markers for early diagnosis, prognosis and therapeutic
targets of gastric carcinoma, among them c-Met [9],
PKP2 and PKP3 [10], Ezrin [33], are the known ones.
Moreover, other molecular biomarkers are currently in
study.
Few previous studies investigated the clinicopathologic
significance of hK6 expression in advanced gastric can-
cer tissues. Thus, in this study, we examined the correl-
ation of hK6 expression with tumor recurrence and
prognosis in advanced gastric cancer. The findings indi-
cate that the expression of hK6 was significantly associ-
ated with TNM stage, vascular invasion, perineural
invasion and poor prognosis for patients with advanced
gastric cancer. Moreover, we found that patients with
positive hK6 expression were more likely to have recur-
rence, and lower RFS and OS rates compared with those
with negative hK6 expression. Multivariate analysis
proved that hK6 expression was a significant independ-
ent prognostic factor of RFS and OS in patients with ad-
vanced gastric cancer. Our findings support that hK6
might be used as a potential biomarker and therapeutic
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sion of hK6 in advanced gastric cancer tissues may pro-
vide valuable information to understand the biological
behavior of gastric cancer.
In conclusion, our study showed that hK6 expression
in advanced gastric cancer significantly correlated with
TNM stage, vascular invasion and perineural invasion as
well as RFS and OS rates. This is a rare report to evalu-
ate hK6 expression and its correlation with tumor recur-
rence and poor prognosis in advanced gastric cancer.
Further studies will be needed to explore the possibilities
whether hK6 might be used as a valuable biomarker in
predicting tumor recurrence and a therapeutic target for
gastric cancer by using serum samples from patients.
And we also will examine the KLK6 at the mRNA level
from the tissues samples next step.
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